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hizuoka, JapanA B S T R A C TObjective: To examine health-related quality of life, we investigated
the effect of adjuvant chemotherapy regimens on utility scores as-
sessed by the EuroQoL-5D (EQ-5D) instrument in a randomized, con-
trolled trial for breast cancer patients after surgery. We also investi-
gated the relationship between Functional Assessment of Cancer
Therapy (FACT) scale scores and EQ-5D utilities. Methods: Patients
were randomly assigned to the following four chemotherapy regimens:
four cycles of anthracycline followed by paclitaxel (ACP), four cycles of
anthracycline-containing regimens followed by docetaxel (ACD), eight
cycles of paclitaxel (PTX), and eight cycles of docetaxel (DTX). Of 1060
registered, the first 300 consecutive patients were included in the cur-
rent utility study. Utility scores were assessed using the EQ-5D instru-
ment at baseline; cycles 3, 5, and 7; 7 months; and 1 year. We also
evaluated the correlation between these scores and FACT-G, -B, and
-Taxane scores at each time point. Results: Utility scores were signifi-
i, Ku
al So
doi:10.1016/j.jval.2011.01.007cantly lower in the DTX group than in the ACP and ACD groups. Mean
utility scores in the DTX group were lowest at 7 months and tended to
remain low for a long time. The combined anthracycline followed by tax-
ane group had significantly higher utility scores that the taxane-alone
group, with no significant difference depending on the type of taxane.
Only the FACT-G social/family well-being subscale had no relationship
withEQ-5D responsesandutility scores.Conclusions: Although the reg-
imens in this studywere similar in that they included taxane, themean
utility scores and longitudinal patterns of utility scores were different
among regimens.
Keywords: anthracycline, breast cancer, EuroQoL-5D, functional assess-
ment of cancer therapy, health-related quality of life, taxane, utility.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In Japan, the number of patient deaths due to breast cancer is
increasing, whereas breast cancer mortality has generally de-
creased since the 1990s in Europe and the United States [1]. In
2007, the death toll from breast cancer in Japan was estimated at
12,000 persons per year, and the age-adjusted mortality was 11.9
per 100,000 persons, making breast cancer second to colorectal
cancer as leading causes of death due to malignant neoplasms in
women [2]. Decreasing deaths due to breast cancer is one of the
most important women’s public health issues.
For increasing numbers ofwomenwith breast cancer, adjuvant
combination chemotherapies are being used to prevent micro-
scopic metastasis. Many kinds of chemotherapy regimens have
been developed in the past two or three decades. Anthracycline-
based regimens (doxorubicin or epirubicin) have proved to be su-
perior to CMF (cyclophosphamide,methotrexate, and fluorouracil)
[1] and are primarily used as adjuvants to standard chemother-
apy in breast cancer patients. Taxane (paclitaxel or docetaxel)
[3,4], one of the most widely used anticancer drugs, is also being
* Address Correspondence to: Takeru Shiroiwa, 1-1-1, Noji-higash
E-mail: t.shiroiwa@gmail.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.used in adjuvant breast cancer patients. Meta-analysis of 13 stud-
ies (N 22,903) shows that taxanes, in combination or in sequence
with anthracycline (AC)-based regimens, significantly improve
disease-free survival (DFS) and overall survival of early breast can-
cer patients [5]. The pooled hazard ratios estimated by the meta-
analysis were 0.83 (95% confidence interval [CI] 0.79–0.87) for DFS
and 0.85 (95% CI 0.79–0.91) for overall survival . The efficacy, how-
ever, of taxane alone regimens without AC or cyclophosphamide
is not known.
The National Surgical Adjuvant Study of Breast Cancer-02 (N-
SAS BC 02) was conducted to compare two general protocols for
treating node-positive breast cancer patients: 1) four cycles of AC-
containing regimens followed by four cycles of taxane and 2) eight
cycles of taxane. Because AC regimens have a risk of causing life-
threatening cardiotoxicity [6], they are contraindicated in patients
with abnormal cardiac function. If taxane regimens are not infe-
rior to AC-based regimens, the use of taxane alone as an alterna-
tive chemotherapy might be increased.
Nevertheless, it is possible that administration of taxane will
cause serious adverse events, such as peripheral neuropathy. It is
satsu, Shiga 525-8577, Japan.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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747V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 6 – 7 5 1well-known that taxane-induced peripheral neuropathy occurs in
proportion to the dose level and cumulative dose. Even if eight-
cycle taxane regimens have a nearly identical efficacy as AC-based
regimens, such adverse events may decrease health-related qual-
ity of life (HRQOL) or expected quality-adjusted life years (QALYs)
[7]. To examine the HRQOL, we included measurement by the
unctional Assessment of Cancer Therapy (FACT) scale [8,9] and
EuroQoL-5D (EQ-5D) [10,11] as secondary end points in N-SAS BC
02 trial. EQ-5D scores are also intended for use in the economic
evaluation of eight-cycle taxane regimens. In this article, we re-
port on utility scores of early breast cancer patients measured by
EQ-5D and the relationship between EQ-5D and FACT scale scores.
In addition, there are few reliable data on utility scores of
breast cancer patients in Japan. Unfortunately, it is rare for longi-
Fig. 1 – Study design and allocation of patients into
treatment groups.
Table 1 – Baseline characteristics of patients shown as num
Characteristic ACP (n  74) ACD (n 
Age in years
40 4 (5.4) 8 (10.
40 to 50 16 (21.6) 14 (18.
50 to 60 41 (55.4) 38 (50.
60 13 (17.6) 15 (20.
Age in years, median 54 53
Performance status
0 64 (86.5) 63 (84.
1 5 (6.8) 9 (12.
Unknown 5 (6.8) 3 (4.0
Tumor size, cm
3 41 (55.4) 42 (56.
3 33 (44.6) 33 (44.
No. of positive lymph nodes
1–3 41 (55.4) 41 (54.
4-9 18 (24.3) 20 (26.
10 15 (20.3) 14 (18.
Surgery
Conserving 31 (41.9) 30 (40.
Mastectomy 41 (55.4) 45 (60.
Other 2 (2.7) 0 (0.0
Hormone receptor
Positive 29 (39.2) 31 (41.
Negative 45 (60.8) 44 (58.
HER2 receptor
Positive 17 (23.0) 20 (26.
Negative 36 (48.6) 31 (41.
Unknown 21 (28.4) 24 (32.0)tudinal HRQOL or utility scores to be collected in Japanese pro-
spective clinical trials. We planned to prospectively evaluate util-
ity scores during treatment as well as 1 year post-treatment in
breast cancer patients receiving four different types of taxane-
containing adjuvant chemotherapy.
Methods
Patients
The N-SAS BC 02 trial included the following eligibility criteria:
age 18 to 70 years, node-positive disease, no metastasis (stages
I-IIIA), no previous hormone or chemotherapy, and an Eastern
Cooperative Oncology Group performance status of 0–1 [12]. Pa-
ients whowere both estrogen receptor and progesterone recep-
or positive were excluded. The study protocol of N-SAS BC 02,
owever, was amended to permit the enrollment of both hormone-
ositive patients from June 2003. Written informed consent was re-
uired from all patients before study enrollment, and the study was
pproved by the institutional review boards of the participating cen-
ers.
Study design and treatment protocols
Based on the 2 2 factorial design, the 1060 eligible patients were
andomly assigned to receive one of the following four regimens:
) four cycles of AC-containing regimens (doxorubicin 60mg/m2 or
pirubicin 75 mg/m2  cyclophosphamide 600 mg/m2 every 3
weeks  4) followed by paclitaxel (175 mg/m2 every 3 weeks  4)
(ACP group), b) four cycles of AC followed by docetaxel (75 mg/m2
every 3 weeks  4) (ACD group), c) eight cycles of paclitaxel (175
mg/m2 every 3 weeks  8) (PTX group) , and d) eight cycles of
ocetaxel (75 mg/m2 every 3 weeks  8) (DTX group).
(percentage of group).
PTX (n  75) DTX (n  75) Total (N  299)
13 (17.3) 10 (13.3) 35 (11.7)
15 (20.0) 25 (33.3) 70 (23.4)
32 (42.7) 28 (37.3) 139 (46.5)
15 (20.0) 12 (16.0) 55 (18.4)
53 51 53
65 (86.7) 62 (82.7) 254 (84.9)
8 (10.7) 7 (9.3) 29 (9.7)
2 (2.7) 6 (8.0) 16 (5.4)
43 (57.3) 43 (57.3) 169 (56.5)
32 (42.7) 32 (42.7) 130 (43.5)
41 (54.7) 41 (54.7) 164 (54.8)
21 (28.0) 21 (28.0) 80 (26.8)
13 (17.3) 13 (17.3) 55 (18.4)
32 (42.7) 31 (41.3) 124 (41.5)
42 (56.0) 44 (58.7) 172 (57.5)
1 (1.3) 0 (0.0) 3 (1.0)
28 (37.3) 29 (38.7) 117 (39.1)
47 (62.7) 46 (61.3) 182 (60.9)
19 (25.3) 18 (24.0) 74 (24.7)
33 (44.0) 31 (41.3) 131 (43.8)ber
75)
7)
7)
7)
0)
0)
0)
)
0)
0)
7)
7)
7)
0)
0)
)
3)
7)
7)
3)23 (30.7) 26 (34.7) 94 (31.4)
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748 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 6 – 7 5 1Randomizationwas performed centrally, andweused themin-
imization method to balance treatment allocation according to
nodal status, surgical procedure, hormone receptor status, HER2
status, tumor diameter, and medical center. The first 300 consec-
utive patients of the randomized patients from the N-SAS BC 02
trial were included in this HRQOL study (Fig. 1). The primary end
point was DFS, defined as time from randomization to the first
occurrence of any of the defined events. HRQOL and cost-effec-
tiveness were two of the secondary end points.
HRQOL assessment
HRQOL was assessed by the Japanese version of the FACT-G scale
[8,9], FACT-B scale [13], FACT-Taxane scale [14], and EQ-5D. The
FACT-G scale is a 27-item patient self-reporting scale that has a
total score (0–108, with 108 for perfect functioning) that consists of
four subscales (physical well-being [PWB], social/family well-be-
ing [SFWB], emotionalwell-being [EWB], and functionalwell-being
[FWB]). The FACT-B and FACT-Taxane scales are subscales for
breast cancer and toxicity of taxane, respectively. The total scores
on FACT-B and FACT-Taxane scales can be obtained by adding
these subscores to total score of FACT-G (144 and 172 for perfect
functioning). The EQ-5D has five dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. There
are three levels in each dimension, and patient responses to the
EQ-5D can be converted to utility scores (0–1, where 1 means per-
fect health in principle) [11]. This five-dimension descriptive sys-
tem can evaluate 243 (35  243) different health states.
Weperformedbaseline assessments of the FACT-G, -B, and -Tax-
ne scales and the EQ-5D between the time of patient random as-
ignments and the start of chemotherapy. Follow-up assessments
ere performed before administration of chemotherapy at cycles 3,
, and 7; 7months; and 1 year after starting adjuvant chemotherapy.
.
Statistical analysis
We calculated descriptive statistics for HRQOL at predetermined
time points. In the case that one or more of the five EQ-5D re-
sponses were not obtained, we treated utility scores at this time
point as missing values. Sample size of HRQOL population in N-
SAS-BC 02 trial was not based on the statistical consideration;
however, when effect size of FACT-G was 10-point and SD of the
FACT-G scale scorewas 15, 75 patients in each groupwere needed.
To detect differences in utility scores among chemotherapy regi-
mens, longitudinal utility scores from EQ-5D were analyzed based
on a linearmixedmodel [15] using theMIXED procedure in SAS 9.1
SAS Institute, Cary, NC). Utility scoreswere analyzed by themodel
ith the baseline scores as the covariate and group, time, and the
nteraction of time and group as fixed effects. The analysis used
estricted maximum likelihood estimation [16] and a compound
ymmetry structure (an unstructured covariance structure was
lso applied as part of a sensitivity analysis). First, there were four
ifferent chemotherapy regimen groups. Second, patients in the
CP and ACD groups were pooled as the AC followed by taxane
roup, whereas those in the PTX andDTX groupswere analyzed as
he taxane-alone group. In the sameway, the ACP and PTX groups
ere combined into the paclitaxel group, and the ACD and DTX
roups were combined into the docetaxel group.
In addition, to examine the influence of demographic and
ackground factors on utility scores, we used another model that
ncluded additional variables such as age, type of hormone recep-
or, HER2 receptor status, surgery, number of positive lymph
odes, and tumor size. Statistical significance for all analyses was
efined as P  0.05 (two sided). To examine the relationship be-
ween HRQOL instruments, we calculated a correlationmatrix be-
ween the EQ-5D (response to five questions and utility score) andACT (FACT-G, -B, -Taxane, and FACT-G subscales) scale scores
ased on the Spearman rank correlation coefficient.
Results
Study population
BetweenNovember 2001 andMay 2003, 300 patientswere enrolled at
64 centers in Japan: 74 patients were randomly assigned to the ACP
group, 75 to the ACD group, 76 to the PTX group, and 75 to the DTX
group. Because therewere no HRQOL data for one patient in the PTX
group (withdrawal of consent), the patient was excluded from
HRQOL population. The baseline characteristics of 299 patients are
shown in Table 1. These characteristics were not different from the
entire intent-to-treat (ITT) population; with the exception of hor-
mone receptor status (39.1% patients were positive in the QOL pop-
ulation and 62.5% in the ITT population). This is because protocol
amendment permitted patients with both estrogen receptor– and
progesterone receptor–positive cancer to enroll in the N-SAS BC 02
trial. Themedian age of the 299patientswas 53 years.More thanhalf
of thepatients hadone to three positivenodes, and in approximately
one fourth of patients, tumors were HER2 positive.
Response to the EQ-5D survey
The numbers and percentages of 299 patients completing the EQ-5D
at cycles 3, 5, and 7; 7months; and 1 year after initiation of treatment
were 294 (98%), 287 (96%), 275 (92%), 262 (88%), and 228 (76%), respec-
tively. The percentage of missing values (at least one of the five
EQ-5D responses was blank) was approximately 2% at each time
point, although the percentage at 1 year was a little high (6.1%). The
pattern of missing values was not different among the four groups.
Fig. 2 – Longitudinal patterns of utility scores by treatment
group. (a) Mean utility scores. (b) Difference from baseline
utility scores.
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749V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 6 – 7 5 1Comparison of utility scores among groups
The mean utility scores and differences from baseline are shown
longitudinally by group in Figure 2. The results show that utility
scores measured by the EQ-5D in the DTX group were lower than
in other groups. In addition, the pattern of utility scores over time
in the DTX group was different from those in the ACP, ACD, and
PTX groups: the lowest score in the DTX group occurred at 7
months from the start of treatment, although utility scores of the
other three groups were lowest at cycle 7 or earlier.
The analysis showed there were significant differences in the
interaction between time and group and group effects (P values
were 0.0061 and 0.0002, respectively; Table 2). Compared with the
DTX group, the utility scores in the ACP and ACD groups were
significantly higher (P values were 0.0048 and 0.0001, respec-
tively), but those in the PTX group were not significantly different
(P 0.269). Least squaresmeans of utility scores at each time point
re presented in Table 3.
The utility scores of the combined AC followed by taxane group
ACP and ACD groups) were significantly higher than the combined
axane-alone group (PTX and DTX groups) (difference  0.054, P 
0.0001; Table 2). On the other hand, there were no significant differ-
ences between the combined paclitaxel group (ACP and PTX groups)
andthecombineddocetaxelgroup(ACDandDTXgroups) (difference
0.002, P 0.889; Table 2). These results did not change when using
n unstructured covariance structure (not shown).
Results from the analysis that included background factors
howed that only age influenced the utility scores (P  0.0396, coef-
cient  –0.015/10 years). Other factors, such as type of hormone
eceptor, HER2 receptor status, surgery, number of positive lymph
odes, and tumor size, did not significantly relate to utility scores. In
he AC followed by taxane group, some patients received epirubicin,
ot doxorubicin. We observed no significant difference when com-
aring the epirubicin regimen with doxorubicin (P 0.126).
Table 2 – Results of the linear mixed-model analysis.
Effect
Baseline
Group
Time
Time  group
Comparison Difference
ACP vs. DTX 0.052
ACD vs. DTX 0.077
PTX vs. DTX 0.021
AC followed by taxane vs. taxane alone 0.054
Paclitaxel vs. docetaxel 0.002
AC, anthracycline; ACD, four cycles of anthracycline-containing regim
paclitaxel; CI, confidence interval; DTX, eight cycles of docetaxel; PTX
* P  0.05.
Table 3 – Estimated utility scores and 95% confidence inter
Time ACP ACD
Cycle 3 0.804 (0.769–0.839) 0.838 (0.803
Cycle 5 0.801 (0.766–0.836) 0.808 (0.773
Cycle 7 0.764 (0.728–0.800) 0.843 (0.806
7 Months 0.822 (0.785–0.859) 0.823 (0.786
1 Year 0.852 (0.811–0.894) 0.853 (0.813
Mean 0.809 (0.783–0.835) 0.833 (0.807–0.85Relationship between the EQ-5D and FACT scales
We calculated the correlation coefficients between the EQ-5D and
the FACT-G, FACT-B and FACT-Taxane scales. Table 4 shows only
he results at cycle 7 (the last time point during chemotherapy)
nd 1 year (the last time point), and other results had almost the
ame pattern of correlation coefficients. The FACT-G SFWB sub-
cale score had no relationship with EQ-5D responses or utility
core (almost all the correlation coefficients are 0.1), although
ther subscale scores and total scores were related at least to the
tility score. We found similar relationships at all the time points.
n addition, the self-care dimension of EQ-5D has little correlation
ith FACT-G, -B, -Taxane, and FACT-G subscale scores. On the
ther hand, there were strong correlations between the FACT-
WB subscale and utility scores and between the FACT-Taxane
nd utility scores. We also observed strong correlations (r 0.6 for
t least one time point) between the following FACT subscales and
Q-5D dimensions: a) FACT PWB subscale and pain/discomfort
imensions of the EQ-5D and b) FACT EWB subscale and the anx-
ety/pain dimension of the EQ-5D.
Discussion
Our analysis showed that theDTX regimen resulted in lowermean
utility scores and a different pattern of utility scores over time
from the ACP, ACD and PTX groups. We found that the only back-
ground factor that significantly influenced the utility score was
patient age. There are not many articles on utility scores of adju-
vant breast cancer patients measured by EQ-5D or other instru-
ments. A review [17] of EQ-5D-based utility scores in cancer pa-
tients found that utility scores of breast cancer patients generally
range from 0.7 to 0.8, which is consistent with our analysis.
According to the interim analysis of the N-SAS BC 02, the sur-
vival curve of the PTX group tended to be lower than that of the
lue P value
75 0.0001*
67 0.0002*
40 0.0001*
33 0.0061*
SE P value 95% CI
0.0185 0.0048* 0.016–0.089
0.0185 0.0001* 0.040–0.113
0.0186 0.2690 0.016–0.057
0.0132 0.0001* 0.028–0.080
0.0131 0.8885 0.028–0.024
followed by docetaxel; ACP, four cycles of anthracycline followed by
ht cycles of paclitaxel; SE, standard error.
f each group at each time point.
PTX DTX
3) 0.783 (0.747–0.818) 0.799 (0.764–0.835)
4) 0.771 (0.735–0.806) 0.758 (0.722–0.794)
9) 0.742 (0.705–0.779) 0.720 (0.685–0.756)
0) 0.785 (0.748–0.822) 0.711 (0.675–0.747)
2) 0.804 (0.765–0.843) 0.793 (0.755–0.831)F va
45.
6.
8.
2.
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, eigval o
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750 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 4 6 – 7 5 1other three groups, and the taxane-alone groupwas not inferior to
the AC followed by taxane group in terms of DFS (hazard ratio 1.26,
95% CI 0.99–1.60, P  0.67). Docetaxel (75 mg/m2) was superior to
aclitaxel (175 mg/m2) when given every 3 weeks in terms of DFS
(hazard ratio 0.81, 95% CI 0.64–1.03, P  0.08) [18]. Because the
tility scores of the AC followed by taxane group were higher than
he taxane-alone group, the AC followed by taxane regimen is
ossibly preferable in terms of QALYs. In addition, because utility
cores of the docetaxel regimen were nearly equal to those of the
aclitaxel regimen fromour analysis,moreQALYs can be obtained
sing the docetaxel regimen than the paclitaxel regimen.
Although the utility scores during chemotherapy decreased
ompared with baseline, the utility scores of all four groups recov-
red to at least baseline level at the 1-year time point. The influ-
nce of chemotherapy seems to disappear by 1 year from the start
f chemotherapy. It is unclear why the utility scores of the DTX
roup were lower at this time point because the lowest utility
core for this group was delayed compared with the other groups,
ut the toxicity of the DTX regimen may be greater and continue
or a long time after completion of chemotherapy. Other than
dema, there were no adverse events frequently observed in the
TX group. Grade 3 or 4 edema was seen in 13.3% of patients in
TX group (n  10), and only one patient in the ACD group expe-
ienced severe edema among the other groups. The utility scores
f patientswith edema (grade 1: 0.789, grade 2: 0.729, grade 3: 0.608
t 7 months) were lower than those without edema (0.824). This
ay have had on impact on the utility scores in the DTX group.
The correlationmatrix showed that the FACT-G SFWB subscale
ad no relationship with EQ-5D responses and utility scores. This
eans that utility scores measured by the EQ-5D do not reflect
ocial and family well-being. A similar result was reported by a
tudy group in Singapore [19]. We found strong correlations be-
tween FACT-PWB subscale and utility scores and between FACT-
Taxane and utility scores. The correlation coefficient between
FACT-PWB subscale and utility scores was greater than that be-
tween FACT-G total scale and utility scores because FACT-PWB
includes questions similar to those of the EQ-5D; for example, “I
am forced to spend time in bed” (GP7) and mobility, “I have pain”
(GP4) and pain/discomfort, and “I feel ill” (GP6) and anxiety/de-
pression. The significant correlation between FACT-Taxane and
utility scores may suggest that the toxicity of taxane has a great
Table 4 – Correlation matrix between EQ-5D and FACT sco
Time Variable
Mobility Self-care Usual act
Cycle 7 PWB 0.438* 0.263 0.484
SFWB 0.030 0.131 0.011
EWB 0.080 0.148 0.191
FWB 0.235 0.208 0.405
TOTAL_G 0.258 0.265 0.346
TOTAL_B 0.262 0.248 0.354
TOTAL_Tax 0.425* 0.298 0.428
1 Year PWB 0.303 0.257 0.468
SFWB 0.066 0.108 0.099
EWB 0.144 0.141 0.222
FWB 0.232 0.207 0.401
TOTAL_G 0.216 0.211 0.381
TOTAL_B 0.225 0.220 0.405
TOTAL_Tax 0.262 0.257 0.428
EQ-5D, EuroQoL-5D; FACT, Functional Assessment of Cancer Therap
well-being; SFWB, social/family well-being; TOTAL_G, total FACT-G s
* Spearman rank correlation coefficient 0.4.
† Spearman rank correlation coefficient 0.6.influence on the utility scores.The minimally important difference (MID) for the utility score
measured by the EQ-5D is not necessarily clear. One study estimated
theMIDas 0.040 for the EQ-5D (US algorithm) and 0.082 for the EQ-5D
(UK algorithm) [20]. Another study reported that the MIDwas 0.07 to
0.12 for EQ-5D (UK algorithm) and 0.06 to 0.09 for EQ-5D (US algo-
rithm) in cancerpatients [21].Although theMID for Japanesepatients
has not been examined, the difference in utility score between ACD
and DTX groups in this studywas 0.077, which can be interpreted as
meaningful according to these previously published criteria.
Patients whowere asked to respond to the HRQOL instruments
are part of a randomized population. Because they are the first 300
consecutive patients andwere not selected using other criteria,we
consider them an unbiased population from the ITT population.
The proportion of hormone receptor–positive patients in the QOL
population is lower than in the ITT population because of protocol
amendment, but the percentages of other background factors are
the almost same. The analysis shows that the status of hormone
receptor does not significantly influence utility scores.
Our study examined longitudinal utility scores of breast cancer
patients during and after four chemotherapy regimens in a random-
ized, controlled trial. Although the regimens in this study were sim-
ilar in that they included taxane, the mean utility scores and longi-
tudinal patterns of utility scoreswere different among the regimens.
Source of financial support: This studywas funded by the Com-
prehensive Support Project for Oncology Research (CSPOR) and for
Health Outcomes Study (CSP-HOR) of Public Health Research
Foundation. The corporate and individual sponsors of this study
arelistedontheCSPORwebsite(http://www.csp.or.jp/contribution_
en.php). The pharmaceutical manufacturer/distributor who had
provided financial contribution as a corporate sponsor took no
part in this study other than providing information relevant to
proper use of the study drug(s). All decisions concerning the plan-
ning, implementation and publication of this study were made by
the executive committee of this study.
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